JP2022512384A5 - - Google Patents
Info
- Publication number
- JP2022512384A5 JP2022512384A5 JP2021533435A JP2021533435A JP2022512384A5 JP 2022512384 A5 JP2022512384 A5 JP 2022512384A5 JP 2021533435 A JP2021533435 A JP 2021533435A JP 2021533435 A JP2021533435 A JP 2021533435A JP 2022512384 A5 JP2022512384 A5 JP 2022512384A5
- Authority
- JP
- Japan
- Prior art keywords
- purified
- asph
- tumor
- vaccine
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862779422P | 2018-12-13 | 2018-12-13 | |
| US62/779,422 | 2018-12-13 | ||
| PCT/US2019/066174 WO2020123912A1 (en) | 2018-12-13 | 2019-12-13 | Inhibition of asph expressing tumor growth and progression |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022512384A JP2022512384A (ja) | 2022-02-03 |
| JP2022512384A5 true JP2022512384A5 (https=) | 2022-12-20 |
Family
ID=71077044
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021533435A Pending JP2022512384A (ja) | 2018-12-13 | 2019-12-13 | Ａｓｐｈ発現腫瘍の成長および進行の阻害 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20220054614A1 (https=) |
| EP (1) | EP3893925A4 (https=) |
| JP (1) | JP2022512384A (https=) |
| KR (1) | KR20210129634A (https=) |
| CN (1) | CN113747914A (https=) |
| CA (1) | CA3123006A1 (https=) |
| WO (1) | WO2020123912A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI852977B (zh) | 2019-01-10 | 2024-08-21 | 美商健生生物科技公司 | 前列腺新抗原及其用途 |
| WO2020223639A1 (en) * | 2019-05-01 | 2020-11-05 | Sensei Biotherapeutics, Inc. | Combination therapies for cancer |
| CR20220220A (es) | 2019-11-18 | 2022-09-20 | Janssen Biotech Inc | Vacunas basadas en calr y jak2 mutantes y sus usos |
| EP4175664A2 (en) | 2020-07-06 | 2023-05-10 | Janssen Biotech, Inc. | Prostate neoantigens and their uses |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011011688A2 (en) * | 2009-07-24 | 2011-01-27 | Rhode Island Hospital | DENDRITIC CELL VACCINES FOR ASPARAGINYL- β - HYDROXYLASE EXPRESSING TUMORS |
| US20140271689A1 (en) * | 2013-03-15 | 2014-09-18 | Panacea Pharmaceuticals | Therapeutic Cancer Vaccine Targeted to HAAH (Aspartyl-[Asparaginyl]-beta-Hydroxylase) |
| IL292510A (en) * | 2013-11-05 | 2022-06-01 | Cognate Bioservices Inc | Combinations of checkpoint inhibitors and therapeutics to treat cancer |
| JP7025119B2 (ja) * | 2014-04-24 | 2022-02-24 | ロード アイランド ホスピタル | アスパラギン酸－β－ヒドロキシラーゼは腫瘍においてエピトープ特異的Ｔ細胞応答を誘導する |
| GB201501017D0 (en) * | 2014-12-23 | 2015-03-04 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers |
| US10995140B2 (en) * | 2015-06-05 | 2021-05-04 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | GM-CSF/CD40L vaccine and checkpoint inhibitor combination therapy |
| JP2019513373A (ja) * | 2016-03-31 | 2019-05-30 | ネオン セラピューティクス， インコーポレイテッド | ネオ抗原およびその使用方法 |
| WO2019217913A1 (en) * | 2018-05-10 | 2019-11-14 | Sensei Biotherapeutics, Inc. | Aspartate beta-hydroxylase chimeric antigen receptors and uses thereof |
-
2019
- 2019-12-13 KR KR1020217021684A patent/KR20210129634A/ko not_active Ceased
- 2019-12-13 EP EP19897172.3A patent/EP3893925A4/en not_active Withdrawn
- 2019-12-13 CN CN201980091889.XA patent/CN113747914A/zh active Pending
- 2019-12-13 JP JP2021533435A patent/JP2022512384A/ja active Pending
- 2019-12-13 WO PCT/US2019/066174 patent/WO2020123912A1/en not_active Ceased
- 2019-12-13 US US17/413,913 patent/US20220054614A1/en active Pending
- 2019-12-13 CA CA3123006A patent/CA3123006A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Mathew et al. | Combining chemotherapy with PD-1 blockade in NSCLC | |
| KR102470294B1 (ko) | 암을 치료하기 위한 항-pd1 항체 및 방사선의 조합 | |
| JP2022512384A5 (https=) | ||
| JP7162535B2 (ja) | 抗ｇｉｔｒ抗体およびその使用 | |
| CN106573977B (zh) | 针对ceacam1的人源化抗体 | |
| JP2018512397A (ja) | 癌治療の有効性を高めるための組成物及び方法 | |
| JP7384896B2 (ja) | 主要組織適合遺伝子複合（ｍｈｃ）クラスｉｉ－発現癌細胞ワクチン、及び統合免疫応答を生じさせるための使用方法 | |
| JP2023036999A (ja) | 免疫応答を調節するためのオキサビシクロヘプタン | |
| JP2022514499A5 (https=) | ||
| US11684656B2 (en) | Combination therapy for malignant diseases | |
| JP2020528449A5 (https=) | ||
| CN112351795A (zh) | 采用抗癌药剂和以包含非典型hla-i及新抗原复合物为靶点的抗体的联合抗癌疗法 | |
| US20210179714A1 (en) | Inhibition of CTLA-4 and/or PD-1 For Regulation of T Cells | |
| JP2021528367A (ja) | 免疫応答を誘導するための組成物 | |
| WO2020216963A1 (en) | Personalized immunotherapy for treatment of cancer | |
| KR20240103062A (ko) | 이중 특이적 항CD3 x MUC16 항체 및 항CTLA-4 항체로 암을 치료하는 방법 | |
| TW202304512A (zh) | 雙特異性t細胞銜接體之給藥 | |
| TWI814752B (zh) | 免疫治療劑、核苷類抗代謝物和鉑類聯合在製備治療腫瘤的藥物中的用途 | |
| RU2021104042A (ru) | Иммунотерапия, нацеленная на антигены kras или her2 | |
| Subudhi et al. | Improving the Therapeutic Benefits of Ipilimumab | |
| HK40005871B (en) | Anti-gitr antibodies and uses thereof | |
| HK40005871A (en) | Anti-gitr antibodies and uses thereof | |
| Turcotte et al. | PolyI: C and CpG synergize with anti-ErbB2 mAb for treatment of breast tumors resistant to immune checkpoint inhibitors. |